SG11201407425SA - Methods for inhibition of shc-1/p66 to combat aging-related diseases - Google Patents

Methods for inhibition of shc-1/p66 to combat aging-related diseases

Info

Publication number
SG11201407425SA
SG11201407425SA SG11201407425SA SG11201407425SA SG11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA SG 11201407425S A SG11201407425S A SG 11201407425SA
Authority
SG
Singapore
Prior art keywords
international
taiwan
shc
dist
east
Prior art date
Application number
SG11201407425SA
Other languages
English (en)
Inventor
Shau-Feng Chang
Chun-Hsien Ma
Kuo-Yi Yang
Original Assignee
Ind Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Tech Res Inst filed Critical Ind Tech Res Inst
Publication of SG11201407425SA publication Critical patent/SG11201407425SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/30—Fuel from waste, e.g. synthetic alcohol or diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11201407425SA 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases SG11201407425SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/727,387 US20140179774A1 (en) 2012-12-26 2012-12-26 Methods for inhibition of shc-1/p66 to combat aging-related diseases
PCT/CN2013/075599 WO2014101366A1 (en) 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases

Publications (1)

Publication Number Publication Date
SG11201407425SA true SG11201407425SA (en) 2014-12-30

Family

ID=50975338

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407425SA SG11201407425SA (en) 2012-12-26 2013-05-14 Methods for inhibition of shc-1/p66 to combat aging-related diseases

Country Status (8)

Country Link
US (1) US20140179774A1 (cg-RX-API-DMAC10.html)
EP (1) EP2838528B1 (cg-RX-API-DMAC10.html)
JP (1) JP6305422B2 (cg-RX-API-DMAC10.html)
KR (2) KR20170027860A (cg-RX-API-DMAC10.html)
CN (1) CN104487069A (cg-RX-API-DMAC10.html)
IN (1) IN2014MN02382A (cg-RX-API-DMAC10.html)
SG (1) SG11201407425SA (cg-RX-API-DMAC10.html)
WO (1) WO2014101366A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
EP3976136A1 (en) 2019-05-30 2022-04-06 Becton, Dickinson and Company Cartridge adapter for drug delivery device
KR20230083169A (ko) 2021-12-02 2023-06-09 대주전자재료 주식회사 다공성 규소-탄소 복합체, 이의 제조방법 및 이를 포함하는 음극 활물질

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09291039A (ja) * 1995-12-26 1997-11-11 Suntory Ltd プロシアニジンを有効成分とする抗肥満剤
DE69633502T2 (de) 1995-12-26 2006-02-23 Suntory Ltd. Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit
GB9906515D0 (en) * 1999-03-22 1999-05-19 Europ I Of Oncology Materials and methods relating to the effects oF P66 expression
WO2000078326A1 (en) 1999-06-18 2000-12-28 Dry Creek Nutrition, Inc. Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
KR100509119B1 (ko) 1999-07-16 2005-08-18 주식회사 엘지생활건강 프로시아니딘 올리고머를 유효성분으로 하는 약제
AU2002250117B2 (en) * 2001-03-15 2007-11-29 Cognitive Clarity Inc. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
EP1256335A1 (de) 2001-05-10 2002-11-13 Cognis France S.A. Verwendung von oligomeren Procyanolidinen
CN1443533A (zh) * 2002-03-07 2003-09-24 程彦杰 原花青素类化合物在用于制备解酒保肝产品方面的用途
KR100531472B1 (ko) * 2002-08-09 2005-11-28 주식회사 이롬 항산화 활성을 가지는 찔레나무 추출물을 포함하는 화장품 조성물 및 상기 추출물의 제조방법
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
JP2005097273A (ja) * 2003-08-19 2005-04-14 Toyo Shinyaku:Kk 運動能力向上組成物
EP1676572A1 (en) 2003-09-26 2006-07-05 Kirin Beer Kabushiki Kaisha Remedy for autoimmune diseases
US20090047368A1 (en) * 2004-11-04 2009-02-19 University Of Tsukuba Polymeric polyphenol extracted from fermented tea, therapeutic agent for mitochondrial disease, preventive/therapeutic agent for diabetes mellitus, and food or beverage
CN100586431C (zh) 2007-09-28 2010-02-03 天津市尖峰天然产物研究开发有限公司 原花青素b2在制备防治糖尿病及血管并发症药物的应用
TWI370736B (en) 2008-12-31 2012-08-21 Ind Tech Res Inst Pharmaceutical composition for treating hepatitis b and heath food for inhibiting hepatitis b virus
US20130123204A1 (en) * 2008-12-31 2013-05-16 Industrial Technology Research Institute Method for treating hepatitis b
CN101822372A (zh) * 2009-03-05 2010-09-08 财团法人工业技术研究院 用以治疗b型肝炎的药学组合物与抑制b型肝炎病毒的保健食品
CA2759025A1 (en) * 2009-04-17 2010-10-21 Cardero Therapeutics, Inc. Methods and compositions for treatment of ischemic conditions and conditions related to mitochondrial function
TWI458487B (zh) 2009-12-30 2014-11-01 財團法人工業技術研究院 藥學組合物之用途
JP2011178728A (ja) 2010-03-02 2011-09-15 Kobe Univ Ampk活性化剤、glut4活性化剤、およびそれらを用いた医薬品・飲食品
EP2689777B1 (en) * 2011-03-22 2018-03-28 Industrial Technology Research Institute Pharmaceutical composition for inducing hepatic regeneration
WO2012163588A2 (en) 2011-05-27 2012-12-06 Unilever Plc Anti-ageing composition
JP2014521702A (ja) * 2011-08-05 2014-08-28 カーデロ セラピューティクス インコーポレイテッド フラボノイド化合物
JP5813576B2 (ja) * 2012-05-22 2015-11-17 アピオン・ジャパン有限会社 サーチュイン1(sirt1)遺伝子活性化剤
CN102688230B (zh) 2012-06-20 2014-12-03 浙江萧山医院 原花青素b2的用途
CN102688501A (zh) 2012-06-20 2012-09-26 浙江萧山医院 原花青素b2磷脂复合物及其制备方法和用途
EP2917220A4 (en) * 2012-11-08 2016-07-20 Cellarouge Pty Ltd MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOLIC COMPOSITIONS

Also Published As

Publication number Publication date
JP2016502532A (ja) 2016-01-28
IN2014MN02382A (cg-RX-API-DMAC10.html) 2015-08-14
EP2838528A4 (en) 2015-09-09
KR20150013629A (ko) 2015-02-05
JP6305422B2 (ja) 2018-04-04
KR20170027860A (ko) 2017-03-10
US20140179774A1 (en) 2014-06-26
EP2838528A1 (en) 2015-02-25
EP2838528B1 (en) 2025-08-06
WO2014101366A1 (en) 2014-07-03
CN104487069A (zh) 2015-04-01

Similar Documents

Publication Publication Date Title
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201809064QA (en) Chimeric neurotoxins
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201903938XA (en) Acylated glp-1/glp-2 dual agonists
SG11201408237YA (en) Compound as wnt signaling inhibitor, composition, and use thereof
SG11201407900WA (en) Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof
SG11201407200TA (en) Liquid formulation
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408791TA (en) Dihydropyrimidine compounds and their application in pharmaceuticals
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201908159QA (en) Dual magl and faah inhibitors
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201806424TA (en) Therapeutic compounds
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction